business
COMPANY BENCHMARKING • UNITED STATES

Amgen Inc. - Company Profile

Access all 5,000+ company profiles through the Benchmarking Pro Membership. Unlock interactive competitor comparison tools that show you how Amgen Inc. stacks up to the competition and put relevant competitor and industry information at your fingertips.


Amgen Inc. - Overview

Brands
Aimovig, Aranesp, Avsola, Blincyto, Corlanor, Enbrel, Epogen, Evenity, Imlygic, Kanjinti, Kyprolis, Lumakras, Mvasi, Neulasta, Neupogen, Nplate, Otezla, Parsabiv, Prolia, Repatha
Description
Amgen is a public company headquartered in California with an estimated 24,200 employees. In the US, the company has a notable market share in at least two industries: Brand Name Pharmaceutical Manufacturing, Biotechnology and Brand Name Pharmaceutical Manufacturing. Their largest market share is in the Biotechnology industry, where they account for an estimated 10.4% of total industry revenue.
Company Details

Registered Name: Amgen Inc.

Company Type: Operating

Exchange: Nasdaq

Headquarters: One Amgen Center Drive Thousand Oaks CA 91320

Website: http://www.amgen.com/

Employees: 24200

Amgen Inc. - Operating Industries and Main Competitors

error_outline To view all of Amgen Inc.'s operating industries and competitors, see purchase options.

Amgen Inc. - Products and Services

  • Brand Name Pharmaceutical Manufacturing in the US

    • Of the 8 core revenue-generating products and services in the Brand Name Pharmaceutical Manufacturing in the US industry, Amgen Inc. offers:
    • Autoimmune prescriptions
    • Oncology prescriptions
    • Other prescriptions

  • Biotechnology in the US

    • Of the 5 core revenue-generating products and services in the Biotechnology in the US industry, Amgen Inc. offers:
    • Human health technologies
error_outline To view Amgen Inc.'s full products and services, see purchase options.

Amgen Inc. - Analyst Insights

Amgen supports Biotechnology Industry Organization’s opposition to COVID-19 vaccine intellectual property waivers

In 2021, Amgen CEO Bob Bradway joined other biotechnology industry leaders in supporting the Biotechnology Industry Association’s declaration recognizing the industry’s role in expanding access to COVID-19 (coronavirus) vaccines while opposing intellectual property (IP) waivers. The association emphasized the importance of biotechnology companies working with governments to support distribution readiness and eliminating certain trade barriers. The declaration also warned that IP waivers may deter future investment and curtail biopharmaceutical innovation.

COVID|Competition|New Activity|ESG


In response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.

Lorem Ipsum text header Report Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.

Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.

error_outline To view all analyst insights on Amgen Inc., see purchase options.

Amgen Inc. - SWOT Analysis

Strengths and weaknesses take into account internal factors, and are based on Amgen Inc.'s performance in comparison to its competitors. Opportunities and Threats focus on external influences, and are based on trends and demand in the Brand Name Pharmaceutical Manufacturing in the US, and Biotechnology in the US industries.
Strengths
Days Receivables: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Annual Turnover: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Weaknesses
Credit Risk: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Revenue per Employee: $xx
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Opportunities
  • AAAAA
  • AAAAA
  • AAAAA
Threats
  • AAAAA
  • AAAAA
  • AAAAA

error_outline To view Amgen Inc.'s full SWOT analysis, see purchase options.

Amgen Inc. - Financial Statements & Ratios

pie_chartAmgen Inc. Income Statement

BALANCE DATE12/31/202112/31/202012/31/201912/31/201812/31/201712/31/2016
Revenue25,979.025,424.023,362.023,747.022,849.022,991.0
Cost of Revenue000000000000000000000000
Cost of Revenue, Non-Cash000000000000000000000000
Gross Profit000000000000000000000000
AAAAAA AAAAAA000000000000000000000000

pie_chartAmgen Inc. Balance Sheet

BALANCE DATE12/31/202112/31/202012/31/201912/31/201812/31/201712/31/2016
Cash and Equivalents7,989.06,266.06,037.06,945.03,800.03,241.0
Short-Term Investments000000000000000000000000
Derivative Assets, Current000000000000000000000000
Restricted Cash and Investments000000000000000000000000
AAAAAA AAAAAA000000000000000000000000

pie_chartAmgen Inc. Cash Flow

BALANCE DATE12/31/202112/31/202012/31/201912/31/201812/31/201712/31/2016
Net IncomeN/AN/AN/AN/AN/AN/A
Income (Loss) From Discontinued Operations000000000000000000000000
Depreciation, Depletion and Amortization000000000000000000000000
Amortization of Financing Costs and Discounts000000000000000000000000
AAAAAA AAAAAA000000000000000000000000

error_outline To view all financial data for Amgen Inc., see purchase options.

GET INSTANT ACCESS WITH BENCHMARKING PRO MEMBERSHIP

100% Money Back Guarantee Digicert Trusted

BENCHMARKING PRO

What's Inside
Benchmarking Pro?

A suite of company and industry data that:

Benchmarks companies against industry averages or like-sized segments, as well as close competitors
Identifies real-world strengths, opportunites, weaknesses and threats
Reveals growth opportunities or red flags in a business growth strategy
LEARN MORE

Included in Report

  • Enterprise History & Synopsis
    Enterprise History & Synopsis
  • Enterprise Financial Statements
    Company Financial Statements
  • Financial Ratios
    Industry Market Share Breakdown
  • Industry Averages
    Industry Competitor Matrix
  • Competitive Landscape
    SWOT Analysis
  • Key Enterprise Personnel
    Products and Services
  • Subsidiaries & Ownership Structure
    Key Company Benchmarks

Why purchase access to Benchmarking Pro?

This profile on Amgen Inc. includes:

  • Company Overview
  • Company Revenue and Employee Data
  • Company Financial Statements
  • Industry Market Share Breakdown
  • Industry Competitor Matrix
  • SWOT Analysis
  • Products and Services
  • Key Company Benchmarks
  • Interconnected Competitor Profiles and Industry Reports
  • Full Access to Benchmarking Pro

The IBISWorld Benchmarking Pro solution enables you to:

  • Understand an enterprise’s competitive landscape and how they perform within a like-sized industry segment.
  • Benchmark companies against industry averages, segment averages and their competitors.
  • Identify real-world strengths, opportunities, weaknesses and threats for companies.
  • Target growth opportunities or spot red flags in a business growth strategy.
  • Toggle between company profiles and industry reports for a 360 degree view of a company's position.

IBISWorld provides profiles on thousands of leading companies around the world. Our clients rely on our information and data to stay up-to-date on business and industry trends across all sectors of the economy. This company profile, along with the corresponding competitor and industry data provided, includes thoroughly researched, reliable and current information that will help you to make faster, better business decisions.

Trusted by More Than 10,000 Clients Around the World

  • IBISWorld client - VISA
  • IBISWorld client - ADP
  • IBISWorld client - Deloitte
  • IBISWorld client - AMEX
  • IBISWorld client - Bank of Montreal